TRAVERE THERAPEUTICS, INC. (TVTX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $62.61, TRAVERE THERAPEUTICS, INC. (TVTX) is priced for today's economics sustained for ~7.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/TVTX

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 10.1% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=5)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

• Travere is effectively a single-drug company built on FILSPARI (sparsentan) for rare kidney disease, and the 10-K says so plainly, that its business depends "almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI" (accession 0001438533-26-000014); Q1 2026 FILSPARI U.S. net product sales grew about 88% year over year to $105.2 million.
• The single biggest event of the year already happened well: on April 13, 2026 the FDA granted full approval of FILSPARI in FSGS, the first medicine ever approved for that condition, expanding the eligible U.S. population to more than 100,000 patients across IgA nephropathy and FSGS.
• The tension is price versus proof: at roughly 10 times sales the stock is priced for a decade of compounding into a 37% operating margin it does not yet earn (it runs about minus 11% today), so watch quarterly FILSPARI net sales and new-patient starts against that trajectory.

Bull Case

The bull case is a launch curve bending the right way at the exact moment its market doubled. FILSPARI U.S. net product sales grew about 88% year over year to $105.2 million in the first quarter of 2026, the company logged 993 new patient start forms, its highest quarterly demand since launch, and total revenue climbed 55.6% year over year. Then the catalyst landed: on April 13, 2026 the FDA granted full approval of FILSPARI for focal segmental glomerulosclerosis, making it the first and only medicine approved for FSGS and, per the company, expanding the addressable U.S. population to more than 100,000 patients across both indications. A drug already accelerating in one rare disease just got a second, larger one with no approved competition.

The economics of the drug are what make the runway matter. Gross margin runs above 98% every quarter, the signature of a specialty therapy where each incremental prescription is almost pure contribution once the commercial infrastructure is built. The 10-K describes FILSPARI's foundation in IgA nephropathy, where it "was granted full approval by the FDA in September 2024" (accession 0001438533-26-000014), and the label is broadening geographically too, with European and Swiss authorizations for IgAN through partners noted in the same filing. Management frames a $3 billion peak U.S. sales potential against current revenue near half a billion, and at 98% gross margin the drop-through on that gap is the entire investment case.

There is a pipeline behind the commercial story and a balance sheet to fund it. The 10-K reports pegtibatinase producing "a 55.1% mean relative reduction in tHcy from baseline" in classical homocystinuria (same accession), a second rare-disease shot on goal beyond sparsentan. The balance sheet scores a perfect solvency reading, with a current ratio of 3.13 and debt already declining, and three of the last four quarters were free-cash-flow positive despite the GAAP losses. Recently the company also crossed into non-GAAP profitability, reporting non-GAAP net income of $4.1 million, or $0.05 per share, in the first quarter. The bull case is a high-margin rare-disease franchise at the inflection where a proven drug meets a doubled market.

Bear Case

Read the valuation methods against each other and the picture is stark: not one standard family reaches the price. The relative-multiple lens puts the stock at 2.4 times what it supports, the forward-growth lens at 3.7 times, and every other method, asset value, earnings power, is further below still. When the conservative frames and the optimistic frames all agree the price is rich, the honest reading is that $56.60 is a bet beyond what any standard method supports, not a disagreement to split the difference on. The market is not valuing what Travere earns; it is valuing what a flawless decade would let it earn.

The arithmetic of that bet is demanding. Priced against sales at about 10.4 times revenue, the stock assumes the business eventually reaches a roughly 37% operating margin, held while revenue grows near its self-funding ceiling for about seven years. It earns about minus 11% at the operating line today. Only about 32% of comparable fast-growers sustained that kind of pace even seven years, and the margin the price assumes is an input to the model, not something the company has demonstrated for a single quarter, its operating margin has swung between positive 15% and negative 29% across the last four. Concentration magnifies every wobble: this is essentially one drug, and the 10-K is explicit that a product that does not "achieve an adequate level of acceptance" leaves the company unable to "generate significant product revenue" (accession 0001438533-26-000014). A single reimbursement setback, a safety signal on a drug that carries liver-monitoring requirements, or a competitor entering FSGS resets the whole thesis.

The capital structure adds a quieter risk the equity price glosses over. Travere carries convertible senior notes, and the 10-K notes that on conversion of the 2029 Notes the company "would be required to repay the principal amount and any conversion premium in any combination of cash and shares" (same accession), a dilution or cash-drain path that activates precisely if the stock keeps rising. Shares are already growing, not shrinking, and book value is just $1.07 per share beneath a $56.60 stock, so there is essentially no asset floor under the equity. The most recent quarter also missed revenue consensus by roughly 9% ($127.2 million against about $139.6 million expected) and posted a GAAP net loss of $37.1 million. The bear case is not that FILSPARI fails; it is that FILSPARI succeeds roughly as hoped and the stock, priced for perfection, still has to grow into a number that leaves no room for the ordinary stumbles a single-product launch reliably produces.

Valuation

Because Travere is not yet earning an operating profit, the price is set against sales, and that framing is the whole story. At $56.60 (July 11, 2026), the stock trades near 10.4 times revenue, a level that only makes sense if the business eventually earns roughly a 37% operating margin and grows revenue near its self-funding ceiling for about seven years. That 37% is an assumption fed into the model, not a level the company has shown; today it runs about minus 11% at the operating line, and its quarterly operating margin has ranged from positive 15% to negative 29% over the last year. The framework labels the priced-in assumption elevated, and the base rate is sobering: only about 32% of comparable fast-growers sustained that growth pace even seven years.

The method families speak in one voice, which is unusual and worth stating plainly: none of them reaches the price. The peer-multiple lens lands at about 2.4 times below the price and the forward-growth lens at 3.7 times below; asset value and earnings power are further down, floored by negative profitability and a $1.07 book value per share. So the spread is not a debate among methods about how expensive the stock is; it is unanimous that the price sits above every standard frame, and the gap is the premium the market pays for the FSGS approval and the launch trajectory. The filing-sourced facts under that premium are real and strong: FILSPARI's full IgAN approval in September 2024 (accession 0001438533-26-000014) and a 98%-plus gross margin that means revenue growth converts to contribution almost dollar for dollar.

Solvency is genuinely not the worry; the company scores a perfect balance-sheet reading, with a 3.13 current ratio and declining debt, and it recently reached non-GAAP profitability. The structural caveat is the convertible notes, which the 10-K describes settling in "any combination of cash and shares" on conversion (same accession), a claim on the equity that grows with the stock. What the buyer at $56.60 is underwriting is not whether FILSPARI works, that question is largely answered, but whether a single-product rare-disease company can compound revenue for the better part of a decade and land near a 37% margin without a reimbursement, safety, or competitive interruption. The price leaves no margin for the interruptions that single-product launches usually deliver.

Catalysts

The defining catalyst of 2026 has already occurred, and favorably. After the FDA extended its review in January 2026 and set a new target action date, and after determining an advisory committee was not required, the agency granted full approval of FILSPARI in FSGS on April 13, 2026, the first and only medicine approved for that disease. Travere frames the approval as expanding the U.S. addressable population to more than 100,000 patients across IgAN and FSGS, and it rests on the Phase III DUPLEX and Phase II DUET head-to-head studies.

The first-quarter print in May carried the commercial detail. Total revenue was $127.2 million against $81.7 million a year earlier, with U.S. net product sales of $124.5 million and FILSPARI net sales up about 88% year over year to $105.2 million on 993 new patient start forms, the highest quarterly demand since launch. Revenue nonetheless missed consensus of roughly $139.6 million by about 9%, the GAAP net loss was $37.1 million ($0.40 per share), and non-GAAP results turned positive at $4.1 million, or $0.05 per share. Management reiterated a $3 billion peak U.S. sales potential for FILSPARI. The forward calendar centers on the FSGS launch ramp now underway, quarterly FILSPARI net sales and new-patient-start trends as the leading indicators, and pipeline progress on pegtibatinase in classical homocystinuria. With the binary regulatory event resolved to the upside, the story shifts from approval risk to execution: whether the doubled market converts into the sales trajectory the price already assumes.

Peer Cohorts (Per Segment, With Filing Citations)

Travere Therapeutics (biopharma, whole company) (reported)

• APLS (APELLIS PHARMACEUTICALS, INC.)
• FY2025 10-K: …on net sales of each licensed product and with minimum quarterly royalty thresholds. In addition, the Company is obligated to pay a specified portion of income it receives from sublicensees. From April 2023 through December 2025, the Company paid $ 7.3 million related to regulatory and sales milestones for SYFOVRE.…
• FY2025 10-K: …SYFOVRE in the United States in March 2023. For the years ended December 31, 2025 and 2024, we generated $586.9 million and $611.9 million, respectively, in U.S. net product revenue from sales of SYFOVRE. We are developing a next-generation therapy by combining SYFOVRE treatment with APL-3007, which is a small…
• ARQT (ARCUTIS BIOTHERAPEUTICS, INC.)
• FY2025 10-K: …of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that offer more symptomatic improvement, have a lower risk of side effects, or are less costly than our current or future product candidates. Our success will be based…
• FY2025 10-K: …light-based therapies. For atopic dermatitis, our primary competitors include topical therapies such as Eucrisa, marketed by Pfizer Inc.; Opzelura, marketed by Incyte Corporation, Vtama, marketed by Organon & Co., and generic and branded versions of low to mid-potency steroids such as hydrocortisone or triamcinolone.…
• CORT (CORCEPT THERAPEUTICS INC)
• FY2025 10-K: …Therapeutics Incorporated (collectively, "Corcept," the "Company," "we," "us," and "our") is a commercial-stage biopharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone…
• FY2025 10-K: Incorporated and Joseph Douglas ("J.D.") Lyon, dated August 3, 2020 (incorporated by reference to Exhibit 10.2 to the registrant's Quarterly Report on Form 10-Q filed on August 4, 2020). 10.17† Severance and Change in Control Agreement by and between Corcept Therapeutics Incorporated and Sean Maduck, dated August 3,…
• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …endocrinology, obesity and related metabolic diseases, and immunology-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors' products or programs are successful (including the development of generic equivalents), the market for…
• FY2025 10-K: …and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other…
• AXSM (AXSOME THERAPEUTICS, INC.)
• FY2025 10-K: …party, and Blackstone. This new direct agreement superseded the prior direct agreement among us, Antecip, a related party, and Hercules that had been entered into in connection with the Hercules Loan Agreement, which terminated automatically upon repayment of our Hercules loan obligations in full on May 8, 2025. F-…
• FY2025 10-K: …competition with respect to our current products and product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. There are…
• ASND (Ascendis Pharma A/S)
• FY2025 20-F: …Anaveon AG, Xilio Therapeutics Inc, Werewolf Therapeutics Inc., Sutro Biopharma Inc. and Philogen SpA. 18 In addition to product-based competition, our TransCon technologies face technology-based competition as we believe other companies are developing or evaluating enhanced drug delivery and sustained release…
• FY2025 20-F: …of once-weekly somapacitan (brand name SOGROYA®) for replacement of endogenous growth hormone in adult patients with GHD in the United States, Japan, Europe, Australia and Saudi Arabia and in pediatric patients with GHD in the United States, Japan, Europe, Canada, Brazil and Saudi Arabia. Pfizer (in collaboration…
• HCM (HUTCHMED (China) Ltd)
• FY2025 20-F: …recorded in liabilities respectively. As at December 31, 2025, the total unrecognized compensation cost was approximately US$ 7,002,000 , which considers expected performance targets and the amounts expected to vest, and will be recognized over the requisite periods. ​ F- 31 Table of Contents 20. Revenue The…
• FY2025 20-F: …companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market drugs or are pursuing the development of therapies in the field of kinase inhibition for cancer and other diseases. Some of these competitive drugs and therapies are based on…
• BCRX (BIOCRYST PHARMACEUTICALS, INC.)
• FY2025 10-K: , we are aware of a number of therapies in development for treatment that, if approved, may compete with BCX17725 (e.g., Quoin Pharmaceuticals Ltd.'s QRX-003 in Phase III, ResVita Bio's Pre-Investigational New Drug, RVB-003, and Azitra Inc.'s ATR-12 in Phase I). Diabetic Macular Edema Avoralstat, our investigational…
• FY2025 10-K: European ORLADEYO business. Pharmakon Loan Agreement On October 8, 2025, we used a portion of the proceeds from the sale of the European ORLADEYO business to pay off in full the outstanding principal balance of $198.7 million and terminate the Pharmakon Loan Agreement (as defined below). Astria Therapeutics, Inc.…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.